United Therapeutics (NASDAQ:UTHR) CEO Sells $5,031,105.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $529.59, for a total transaction of $5,031,105.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $21,455,279.67. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $524.28 on Friday. The stock has a market capitalization of $22.98 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 1.89 and a beta of 0.84. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $548.12. The company has a 50 day moving average price of $490.39 and a 200 day moving average price of $468.38.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm’s revenue was up 7.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.19 earnings per share. On average, sell-side analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Wells Fargo & Company increased their price target on United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. Royal Bank Of Canada boosted their price objective on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Finally, UBS Group lifted their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $548.09.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Torren Management LLC acquired a new position in shares of United Therapeutics in the 4th quarter valued at about $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the period. WealthCollab LLC grew its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. grew its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics in the 4th quarter valued at approximately $31,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.